Affiliation:
1. Breast & Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan
2. Medical Oncology, Osaka International Cancer Institute, Osaka, Japan
Abstract
Despite advances in the treatment of hormone receptor-positive, HER2- metastatic breast cancer, the disease is rarely curable. In this review, we focus on the use of CDK4/6 inhibitors, examining clinical experience and the mechanisms underlying the development of resistance, and evaluating treatment options after failure to respond to CDK4/6 inhibitors. Current basic research supports the use of mammalian target of rapamycin inhibitors after CDK4/6 inhibitor failure; however, more data are needed, particularly regarding treatment sequencing. Real-world data studies may help to fill the current knowledge gap, particularly where large-scale randomized controlled studies are not feasible.
Subject
Cancer Research,Oncology,General Medicine
Reference66 articles.
1. Globocan fact sheet: Japan (2018). http://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf
2. Projected cancer statistics (2018). https://ganjoho.jp/en/public/statistics/short_pred.html
3. Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project
4. Advances in treatment and care in metastatic breast cancer (MBC): are there MBC patients who are curable?
5. Japanese Breast Cancer Society. Clinical Practice Guidelines for Breast Cancer Treatment [in Japanese]. Kanehara Shuppan, Tokyo (2018). http://jbcs.gr.jp/guidline/2018/about/
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献